VRDN Viridian Therapeutics notches narrow Q4 2025 EPS beat but shares fall 358 percent on lukewarm investor sentiment CME Group Inc CME Faces Evolving Competitive Landscape as CFTC Reviews Commitments of Traders Reporting Framework Amid Prediction Market Commodity Expansion NXG NXG reports quarterly results with key metrics unavailable investors await detailed financial disclosure GTLB GitLab tops Q1 2026 EPS forecasts by 281 percent shares post mild gains in daily trading PMTS Q1 2026 Earnings EPS Misses Estimates Despite Strong Stock Rally CMG Q1 2026 Earnings EPS Misses Estimate as Revenue Data Remains Undisclosed CRDL Q4 2025 Earnings Narrower Loss Surpasses Estimates Amid Clinical Progress Immunovant Q1 2026 Earnings WiderThanExpected Loss as Pipeline Investment Continues WSBCO Q1 2026 Earnings Preferred Stock Series B Beats EPS Estimates Amid Stable Operations PLXS Q1 2026 Earnings EPS Beat of 678 Surprises Stock Slips 285